Impact of Treatment Delay in Head and Neck Mucosal Melanoma on Overall Patient Survival

Overview

Journal J Neurol Surg B Skull Base

Publisher Thieme

Date 2024 Jul 5

PMID 38966299

Authors

Elaine C Martin

Arash Abiri

Kotaro Tsutsumi

Khodayar Goshtasbi

Sina J Torabi

Edward C Kuan

Affiliations

Soon will be listed here.

Abstract

Head and neck mucosal melanoma (HNMM) is a rare malignancy with high mortality. This study evaluates the impact of treatment delays on overall survival in HNMM. A retrospective review of patients with surgically managed HNMM treated with adjuvant radiation was performed from the 2004-2016 National Cancer Database. Durations of diagnosis-to-treatment initiation (DTI), surgery-to-radiotherapy initiation (SRT), duration of radiotherapy (RTD), surgery-to-immunotherapy initiation (SIT), diagnosis-to-treatment end (DTE), and total treatment package (TTP) were calculated. A total of 1,011 patients (50.7% female, 90.5% Caucasian) met inclusion criteria. Median DTI, SRT, RTD, SIT, DTE, and TTP were 30, 49, 41, 102, 119, and 87 days, respectively. Only longer DTE was associated with decreased mortality (hazard ratio, 0.720; 95% confidence interval, 0.536-0.965; = 0.028). DTI, SRT, RTD, SIT, and TTP do not significantly affect overall survival in patients with HNMM who undergo surgery and adjuvant radiation. Longer DTE is associated with improved survival in this population. 4.

References

McLaughlin C, Wu X, Jemal A, Martin H, Roche L, Chen V . Incidence of noncutaneous melanomas in the U.S. Cancer. 2005; 103(5):1000-7. DOI: 10.1002/cncr.20866. View

Wushou A, Hou J, Zhao Y, Miao X . Postoperative adjuvant radiotherapy improves loco-regional recurrence of head and neck mucosal melanoma. J Craniomaxillofac Surg. 2015; 43(4):553-8. DOI: 10.1016/j.jcms.2015.02.011. View

Gilain L, Houette A, Montalban A, Mom T, Saroul N . Mucosal melanoma of the nasal cavity and paranasal sinuses. Eur Ann Otorhinolaryngol Head Neck Dis. 2014; 131(6):365-369. DOI: 10.1016/j.anorl.2013.11.004. View

Jethanamest D, Vila P, Sikora A, Morris L . Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol. 2011; 18(10):2748-56. PMC: 3155852. DOI: 10.1245/s10434-011-1685-4. View

Jarrom D, Paleri V, Kerawala C, Roques T, Bhide S, Newman L . Mucosal melanoma of the upper airways tract mucosal melanoma: A systematic review with meta-analyses of treatment. Head Neck. 2016; 39(4):819-825. DOI: 10.1002/hed.24652. View

Qatanani A, Eide J, Harris J, Brant J, Palmer J, Adappa N . The Impact of Delay in Treatment on Survival in Surgically Managed Sinonasal Undifferentiated Carcinoma. J Neurol Surg B Skull Base. 2023; 84(4):320-328. PMC: 10317562. DOI: 10.1055/s-0042-1755601. View

Li S, Wu X, Yan X, Zhou L, Chi Z, Si L . Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J Immunother Cancer. 2022; 10(2). PMC: 9066368. DOI: 10.1136/jitc-2021-004036. View

Xiong D, Barriera-Silvestrini P, Knackstedt T . Delays in the surgical treatment of melanoma are associated with worsened overall and melanoma-specific mortality: A population-based analysis. J Am Acad Dermatol. 2022; 87(4):807-814. DOI: 10.1016/j.jaad.2022.06.1190. View

Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V . Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol. 2012; 5(8):739-53. PMC: 3466987. View

10.

Gal T, Silver N, Huang B . Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011; 121(9):2026-33. DOI: 10.1002/lary.21925. View

11.

Tsutsumi K, Ahmed K, Goshtasbi K, Torabi S, Mohyeldin A, Hsu F . Impact of esthesioneuroblastoma treatment delays on overall patient survival. Laryngoscope. 2022; 133(4):764-772. DOI: 10.1002/lary.30136. View

12.

Chang A, Karnell L, Menck H . The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83(8):1664-78. DOI: 10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g. View

13.

Yin G, Guo W, Chen X, Liu Z, Huang Z . [Clinical characteristic and prognostic analyses of 117 cases of head and neck mucosal melanoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018; 53(9):668-674. DOI: 10.3760/cma.j.issn.1673-0860.2018.09.006. View

14.

Nathan P, Ascierto P, Haanen J, Espinosa E, Demidov L, Garbe C . Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019; 119:168-178. DOI: 10.1016/j.ejca.2019.07.010. View

15.

Goel A, Lee J, Wang M, Suh J . Treatment delays in surgically managed sinonasal cancer and association with survival. Laryngoscope. 2019; 130(1):2-11. DOI: 10.1002/lary.27892. View

16.

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

17.

Morse E, Berson E, Fujiwara R, Judson B, Mehra S . Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association. Otolaryngol Head Neck Surg. 2018; 160(2):267-276. DOI: 10.1177/0194599818797605. View

18.

Gore M, Zanation A . Survival in Sinonasal Melanoma: A Meta-analysis. J Neurol Surg B Skull Base. 2013; 73(3):157-62. PMC: 3424013. DOI: 10.1055/s-0032-1301400. View

19.

Moreno M, Roberts D, Kupferman M, DeMonte F, El-Naggar A, Williams M . Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer. 2010; 116(9):2215-23. DOI: 10.1002/cncr.24976. View

20.

Marcus D, Marcus R, Prabhu R, Owonikoko T, Lawson D, Switchenko J . Rising incidence of mucosal melanoma of the head and neck in the United States. J Skin Cancer. 2012; 2012:231693. PMC: 3518053. DOI: 10.1155/2012/231693. View